Document:

Exhibit 4.4

 

WAIVER AND CONSENT AGREEMENT

 

This Waiver and Consent (the “Waiver and
Consent”) is made and entered into as of June 9, 2022, by and between BIMI International Medical Inc., a Delaware corporation
(the “Company”), and ________________, a _________________ Company (the “Investor”). Capitalized
terms used and not otherwise defined herein shall have the meanings set forth for such terms in the November Purchase Agreement (as defined
below).

 

WHEREAS, pursuant to a Securities Purchase Agreement,
dated as of November 17, 2021 (the “November Purchase Agreement”), among the Company, the Investor and another institutional
investor named therein (the “Other Investor” and together with the Investor, the “November Investors”),
the November Investors purchased from the Company, and the Company issued to the November Investors certain senior secured convertible
notes, in an aggregate principal amount of $7,800,000 (the “Notes”), convertible in to shares of the Company’s
Common Stock (as defined in the November Purchase Agreement) and warrants to purchase Common Stock (the “November Warrants”);

 

WHEREAS, pursuant to Section 4(k) of the November
Purchase Agreement, the Company is prohibited, for the period commencing on the date thereof and ending on the date immediately following
the 60th calendar day after the Applicable Date (as defined therein), from issuing, offering, selling, granting any option or right to
purchase, or otherwise disposing of (or announcing any issuance, offer, sale, grant of any option or right to purchase or other disposition
of) any equity security or any equity-linked or related security (including, without limitation, any “equity security” (as
that term is defined under Rule 405 promulgated under the 1933 Act), any Convertible Securities (as defined therein), any preferred stock
or any purchase rights;

 

WHEREAS, pursuant to Section 14(b) of the Notes,
at all times prior to the Defeasance Time (as defined in the Notes), the Company is not permitted to incur or guarantee, assume or suffer
to exist any Indebtedness (other than (i) Indebtedness (as defined in the Notes) evidenced by the Notes and (ii) other Permitted Indebtedness
(as defined in the Notes);

 

WHEREAS, pursuant to a Securities Purchase Agreement,
dated as of May 18, 2020, as amended on February 24, 2021 (as so amended, the “February Purchase Agreement”), among
the Company and the investors named therein (the “February Investors” and together with the November Investors, the
“Investors”), on February 26, 2021, the February Investors purchased from the Company, and the Company issued to the
February Investors certain warrants to purchase shares of Common Stock (the “February Warrants” and together with the
November Warrants, the “Warrants”);

 

WHEREAS, the Company desires to enter into a securities
purchase agreement, substantially in the form provided to the Investor prior to the date hereof (the “New SPA”), pursuant
to which the Company will issue and sell to the chairman of the Company’s board of directors (the “Chairman”),
an aggregate of 12,500,000 shares (the “New Shares”) of the Company’s Common Stock, at a purchase price of $0.40
per share and, pending shareholder approval of the New Offering, the Chairman will provide the Company with a $5 million subordinated
promissory note (the “Chairman’s Note”), which will become due and payable immediately if the New Offering is
not approved by the Company’s stockholders or, upon approval by the Company’s stockholders and the issuance of the New Shares,
the Chairman’s Note will be discharged in full (the “New Offering”); and

 

     

     

    

 

WHEREAS, the issuance of the Chairman’s Note
and the New Shares in the New Offering are not permitted pursuant to Section 14(b) of the Notes and does not qualify as an issuance of
Excluded Securities under the November Purchase Agreement; and

 

WHEREAS, Section 9(e) of the November Purchase
Agreement and Section 8(e) of the February Purchase Agreement provide that no provision of the November Purchase Agreement or the February
Purchase Agreement, as applicable, may be amended or waived other than by an instrument in writing signed by the Company and the holders
of at least 65% of the Registrable Securities (as defined in those certain registration rights agreements referred to therein, each a
“Registration Rights Agreement” and together, the “Registration Rights Agreements”)) (the “SPA
Required Holders”);

 

WHEREAS, Section 16 of the Notes provides that
an amendment, modification or waiver of the terms of the Notes must be approved by the prior written consent of the holders of Notes
representing at least 65% of the aggregate principal amount of Notes outstanding (the “Note Required Holders” and
together with the SPA Required Holders, the “Required Holders”);

 

WHEREAS, the Company and the Investor desire to
waive certain terms of the November Purchase Agreement, the February Purchase Agreement, the Notes and the Warrants, and provide written
consent for the New Offering and the issuance of the Chairman’s Note and the New Shares contemplated thereby, such waiver and consent
to be effective at the Effective Time (as defined below);

 

WHEREAS, in consideration for the Investor providing
its waiver and consent hereof, the Company agrees that: (i) it will use $500,000 of the proceeds from the New Offering to pay down amounts
outstanding under the undersigned Investor’s Notes, with such payments to be made as follows, (a) $250,000 upon issuance of the
Chairman’s Note and (b) $250,000 within two (2) business days of the receipt by the Company of shareholder approval for the New
Offering (the “Use of Proceeds Condition”) and (ii) the New SPA will be signed and the New Offering and all related
transactions, including those contemplated by this Waiver and Consent, will be publicly announced by the Company no later than 5:00 pm
E.T. on June 10, 2022 (the “Required Disclosure Time”).

 

NOW THEREFORE, in consideration of the mutual agreements
herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties
hereto agree as follows:

 

		1.	Waiver and Consent. Effective as of the Effective Time:

 

		(a)	Subject to Section 1(c) below, the Investor hereby consents to the Company’s entry into the New SPA and the issuance of the
Chairman’s Note and the New Shares contemplated thereby, on the terms and subject to the conditions set forth therein and, solely
with respect to the transactions contemplated by the New SPA, hereby waives any restriction, covenant or other obligations of the Company
in the November Purchase Agreement, the February Purchase Agreement, the Notes, the Warrants or any other transaction document entered
into between the parties in connection with the transactions contemplated thereby, solely in order for the Company to enter into, consummate
the transactions contemplated by, and perform its obligations under, the New SPA, and to issue the Chairman’s Note and the New Shares.

 

    2

     

    

 

		(b)	Solely with respect to the issuance of the Chairman’s Note and the New Shares pursuant to the New SPA, and not with respect
to any other Subsequent Placement, the Investor hereby waives the right of participation as set forth in Section 4(o) of the November
Purchase Agreement.

 

		(c)	Solely with respect to the entry in to the New SPA in respect of the New Offering, the Investor hereby agrees that, notwithstanding
the language set forth in Section 2(b) of the Warrants and Section 7(a) of the Notes, and any similar language present in any other equity
or equity-linked instruments of the Company held by such Investor as of the date hereof (the “Other Instruments”),
the Existing Security Adjustments (as defined below) shall be applied to the Notes, the Warrants and any Other Instruments upon the Company’s
receipt of shareholder approval for the New Offering. As used herein, “Existing Security Adjustments” refers to the
exercise and/or conversion price adjustments contemplated in the Notes, the Warrants and any Other Instruments, resulting in a decrease
in the applicable exercise price or conversion price thereof, as applicable, to $0.40 per share; provided that in no event shall any exercise
price or conversion price be increased as a result of the Existing Security Adjustments.

 

		(d)	As a condition to the waiver and consent provided herein, the Company hereby acknowledges and agrees that it will comply with the
Use of Proceeds Condition and make the disclosure set forth in the recitals and in Section 4 hereof by the Required Disclosure Time.

 

		(e)	Notwithstanding the foregoing, except as expressly provided in subsection (c) above, nothing herein shall be deemed to amend, modify
or waive any adjustments to the conversion price of the Notes, the exercise price of the Warrants, or any conversion or exercise price
contained in any Other Instruments, as applicable, that may, from time to time, occur in accordance with the terms thereof upon the Company’s
issuance of the Chairman’s Note, the New Shares, and/or any security issuable upon conversion or exercise thereof, as applicable.

 

		2.	Conditions to Effectiveness of Waiver and Consent. This Waiver and Consent shall become effective (the “Effective
Time”) upon the execution and delivery of this Waiver and Consent (and/or consents in the form of this Waiver and Consent (each,
an “Other Consent”)) by the Company and the Required Holders.

 

    3

     

    

 

		3.	No Implied Consent or Waiver. Except as expressly set forth in this Waiver and Consent, this Waiver and Consent shall not,
by implication or otherwise, limit, impair, constitute a waiver of or otherwise affect any rights or remedies of the Investors under the
November Purchase Agreement, the February Purchase Agreement, the Registration Rights Agreements, the Notes, the Warrants, any Other Instruments
or any other transaction documents entered into in respect thereof (collectively, the “Existing Transaction Documents”),
or alter, modify, amend or in any way affect any of the terms, obligations or covenants contained in the Existing Transaction Documents,
all of which shall continue in full force and effect. Nothing in this Waiver and Consent shall be construed to imply any willingness on
the part of the Investor to agree to or grant any similar or future amendment, consent or waiver of any of the terms and conditions of
any of the Existing Transaction Documents.

  

		4.	Disclosure of Transaction. On or before the Required Disclosure Date, the Company shall disclose in a Current Report on Form
8-K all of the material terms of the transactions contemplated hereby (the “Cleansing Release”). From and after dissemination
of the Cleansing Release, the Company shall have disclosed all material, non-public information (if any) provided to the Investor by the
Company or any of its Subsidiaries or any of their respective officers, directors, employees or agents in connection with the transactions
contemplated hereby. To the extent that the Company delivers any material, non-public information to the Investor from and after the Cleansing
Release without the Investor’s express prior written consent, the Company hereby covenants and agrees that the Investor shall not
have any duty of confidentiality to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, affiliates
or agent with respect to, or a duty to the to the Company, any of its Subsidiaries or any of their respective officers, directors, employees,
affiliates or agent or not to trade on the basis of, such material, non-public information. The Company shall not disclose the name of
the Investor in any filing, announcement, release or otherwise, unless such disclosure is required by law or regulation. In addition,
effective upon and after the Cleansing Release, the Company acknowledges and agrees that any and all confidentiality or similar obligations
under any agreement, whether written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors,
affiliates, employees or agents, on the one hand, and the Investor or any of its affiliates, on the other hand, shall terminate and be
of no further force or effect. The Company understands and confirms that the Investor will rely on the foregoing representations in effecting
transactions in securities of the Company.

 

		5.	Incorporation by Reference. Each of Sections 9(a) (Governing
                                            Law; Jurisdiction; Jury Trial), 9(b) (Counterparts), 9(d) (Severability; Maximum
                                            Payment Amounts), 9(e) (Entire Agreement; Amendments); 9(f) (Notices);
                                            9(g) (Successors and Assigns) 9(j) (Further Assurances) and 9(l) (Construction)
                                            of the November Purchase Agreement are hereby incorporated herein by reference to refer to
                                            this Waiver and Consent, mutatis mutandis.

 

    4

     

    

 

		6.	Most Favored Nation. The Company hereby represents and warrants as of the date hereof and covenants and agrees from and after
the date hereof that none of the terms offered to any Person (including, for the avoidance of doubt, the Other Investor) with respect
to any consent, release, amendment, settlement or waiver relating to the terms, conditions and transactions contemplated hereby (each
a “Settlement Document”), is or will be more favorable to such Person than those of the Investor and this Waiver and
Consent. If, and whenever on or after the date hereof, the Company enters into a Settlement Document, then (i) the Company shall provide
notice thereof to the Investor immediately following the occurrence thereof and (ii) the terms and conditions of this Consent shall be,
without any further action by the Investor or the Company, automatically amended and modified in an economically and legally equivalent
manner such that the Investor shall receive the benefit of the more favorable terms and/or conditions (as the case may be) set forth in
such Settlement Document, provided that upon written notice to the Company at any time the Investor may elect not to accept the benefit
of any such amended or modified term or condition, in which event the term or condition contained in this Waiver and Consent shall apply
to the Investor as it was in effect immediately prior to such amendment or modification as if such amendment or modification never occurred
with respect to the Investor. The provisions of this Section 6 shall apply similarly and equally to each Settlement Document.

 

		7.	Independent Nature of Investor’s Obligations and Rights.
                                            The obligations of the Investor under this Waiver and Consent are several and not joint with
                                            the obligations of the Other Investor, and the Investor shall not be responsible in any way
                                            for the performance of the obligations of any Other Investor under any Other Consent. Nothing
                                            contained herein or in any Other Consent, and no action taken by the Investor pursuant hereto,
                                            shall be deemed to constitute the Investor and Other Investors as a partnership, an association,
                                            a joint venture or any other kind of entity, or create a presumption that the Investor and
                                            Other Investors are in any way acting in concert or as a group with respect to such obligations
                                            or the transactions contemplated by this Consent or any Other Consent and the Company acknowledges
                                            that, to the best of its knowledge, the Investor and the Other Investors are not acting in
                                            concert or as a group with respect to such obligations or the transactions contemplated by
                                            this Consent or any Other Consent. The Company and the Investor confirm that the Investor
                                            has independently participated in the negotiation of the transactions contemplated hereby
                                            with the advice of its own counsel and advisors. The Investor shall be entitled to independently
                                            protect and enforce its rights, including, without limitation, the rights arising out of
                                            this Consent, and it shall not be necessary for any Other Investor to be joined as an additional
                                            party in any proceeding for such purpose.

 

[Signature Page Follows]

 

    5

     

    

 

IN WITNESS WHEREOF, the parties hereto have caused
this Waiver and Consent to be executed by their respective officers thereunto duly authorized as of the day and year first above written.

 

	 	BIMI INTERNATIONAL MEDICAL INC.
	 	 	 
	 	By: 	                              
	 	Name: 	 
	 	Title:	 
	 	 	 
	 	 
	 	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

 

6Exhibit 10.1

 

THIRD OMNIBUS AMENDMENT

 

This Third Omnibus Amendment (“Third
Omnibus Amendment”) is made and entered into as of July 1, 2022 (“Amendment Effective Date”), by and between,
on the one hand, Augmedix Operating Corp. f/k/a Augmedix, Inc. (“Augmedix”) and, on the other hand, Dignity Health
(“DH”), Dignity Health Medical Foundation (“DHMF”), and Pacific Central Coast Health Centers (“PHC”
and, together with the DH and DHMF, the “Client”), and amends:

 

		(1)	That certain Amended and Restated Statement of Work, dated January 24, 2019, as amended, by and between
DH and Augmedix (the “DH-SOW No. 1”); and

 

		(2)	That certain Statement of Work No. 2, dated March 2, 2020, as amended, by and between DH and Augmedix
(the “DH-SOW No. 2”); and

 

		(3)	That certain Statement of Work, dated July 3, 2016, as amended, by and between DHMF and Augmedix
(the “DHMF-SOW”); and

 

		(4)	That certain Statement of Work, dated January 26, 2016, as amended, by and between PHC and Augmedix
(the “PHC-SOW” and, together with the DH-SOW No. 1, DH-SOW No. 2, and DHMF-SOW, the “Dignity
SOW(s)”).

 

WHEREAS, Dignity Health (for itself
and on behalf of its affiliates) and Augmedix entered into that certain Services Agreement, dated September 1, 2015 (the “Agreement”).

 

NOW, THEREFORE, in consideration
of the mutual benefits and promises between the parties, the sufficiency of which each party hereby acknowledges, the Dignity SOWs are
hereby amended as follows:

 

1.     Term. Notwithstanding anything to the contrary in the Dignity SOWs, this Third Omnibus Amendment extends the Term of
the Dignity SOWs through and including June 30, 2023, unless earlier terminated in accordance with the Agreement.

 

2.     CommonSpirit Enterprise Agreement. Notwithstanding
the extension of the Dignity SOWs through and including June 30, 2023, the parties understand and agree that Augmedix and the CommonSpirit
Health (“CommonSpirit”) intend to discuss and negotiate in good faith the terms and conditions of an enterprise wide
CommonSpirit agreement for the provision of the Services to its member organizations. Upon execution of a definitive enterprise agreement
between Augmedix and CommonSpirt, the Agreement and associated Dignity SOWs shall terminate and the enterprise agreement between Augmedix
and CommonSpirit will govern Augmedix’s provision of the Services to all CommonSpirit member organizations, including DH, DHMF and
PHC.

 

3.     General. Capitalized terms used but not otherwise defined herein shall have the same meaning as in the Dignity SOWs
and the Agreement. This Third Omnibus Amendment is hereby incorporated into the Dignity SOWs by reference. Except as expressly amended
herein, all other terms of the Dignity SOWs are hereby confirmed and remain in full force and effect. To the extent that there is any
conflict between the terms of this Third Omnibus Amendment and those of the Agreement or the Dignity SOWs, the terms of this Third Omnibus
Amendment shall control. This Third Omnibus Amendment may be executed in several counterparts, all of which taken together shall constitute
one single agreement between the parties and any full and complete copy thereof shall constitute an original. When signed in pen ink,
such documents may be delivered by facsimile transmission or by scanned email attachment, and said copies shall be treated in all respects
as original.

 

[SIGNATURE PAGE FOLLOWS]

 

    	Omnibus Amendment
Augmedix – Dignity Health
	 	Page 1

     

    

 

AGREED AND ACCEPTED 

 

	DIGNITY HEALTH	 	AUGMEDIX Operating Corp. F/K/A Augedix Inc.
	By 	/s/ Kelley Moore	 	By 	/s/ Jon Hawkins
	Name	Kelley Moore	 	Name	Jon Hawkins
	Title	System VP, Vendor Mgmt & Contracting	 	Title	CRO
	Date	June 8, 2022	 	Date 	June 9, 2022

 

	DIGNITY HEALTH MEDICAL FOUNDATION	 	 	 
	By 	/s/ Kelley Moore	 	 	 
	Name	Kelley Moore	 	 	 
	Title	System VP, Vendor Mgmt & Contracting	 	 	 
	Date	June 8, 2022	 	 	 
	 	 	 	 	 
	PACIFIC CENTRAL COAST HEALTH CENTERS	 	 	 
	By 	/s/ Kelley Moore	 	 	 
	Name	Kelley Moore	 	 	 
	Title	System VP, Vendor Mgmt & Contracting	 	 	 
	Date	June 8, 2022	 	 	 

 

    	Omnibus Amendment
Augmedix – Dignity Health
	 	Page 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]